A prospective study of XELOX plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer (KSCC 0902)

BACKGROUND: This study was designed to evaluate the efficacy and safety of XELOX plus bevacizumab in a Japanese metastatic colorectal cancer population that included elderly patients. METHODS: This was a multicenter, single-arm, open-label prospective study. The major inclusion criteria were previou...

Descripción completa

Detalles Bibliográficos
Autores principales: Ogata, Yutaka, Shimokawa, Mototsugu, Tanaka, Takaho, Emi, Yasunori, Oki, Eiji, Saeki, Hiroshi, Sadanaga, Noriaki, Kusumoto, Tetsuya, Touyama, Tetsuo, Kimura, Masami, Baba, Hideo, Akagi, Yoshito, Shirouzu, Kazuo, Maehara, Yoshihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4824802/
https://www.ncbi.nlm.nih.gov/pubmed/26338269
http://dx.doi.org/10.1007/s10147-015-0895-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4824802/
https://www.ncbi.nlm.nih.gov/pubmed/26338269
http://dx.doi.org/10.1007/s10147-015-0895-3

Ejemplares similares